Evoke Pharma Revenue 2012-2024 | EVOK

Evoke Pharma revenue from 2012 to 2024. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Evoke Pharma Annual Revenue
(Millions of US $)
2023 $5
2022 $3
2021 $2
2020 $0
2019 $
2018 $
2017 $
2016 $
2015 $
2014 $
2013 $
2012 $
2011 $
Evoke Pharma Quarterly Revenue
(Millions of US $)
2024-09-30 $3
2024-06-30 $3
2024-03-31 $2
2023-12-31 $2
2023-09-30 $2
2023-06-30 $1
2023-03-31 $1
2022-12-31 $1
2022-09-30 $1
2022-06-30 $0
2022-03-31 $0
2021-12-31 $0
2021-09-30 $1
2021-06-30 $0
2021-03-31 $0
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2011-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.006B $0.005B
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.395B 6.36
Dr Reddy's Laboratories (RDY) India $11.853B 22.68
BridgeBio Pharma (BBIO) United States $4.426B 0.00
Bausch Health Cos (BHC) Canada $2.931B 2.13
Amphastar Pharmaceuticals (AMPH) United States $2.186B 13.14
Supernus Pharmaceuticals (SUPN) United States $2.000B 27.23
Taysha Gene Therapies (TSHA) United States $0.506B 35.29
Personalis (PSNL) United States $0.245B 0.00
Assembly Biosciences (ASMB) United States $0.096B 0.00
Sol-Gel Technologies (SLGL) Israel $0.015B 0.00
Teligent (TLGT) United States $0.000B 0.00